/ICVX
ICVX Stock - Icosavax, Inc.
Healthcare|BiotechnologyNASDAQ
$15.31-0.91%
$0.14 (-0.91%) • Feb 16
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.84
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.69
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+76.4%upside
Target: $27.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ICVX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$15.16 – $15.46
TARGET (TP)$27.00
STOP LOSS$14.09
RISK/REWARD1:9.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.28
52W High$16.11
52W Low$4.75
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|
| Revenue | $582,000 | $7.80M | $1.62M | N/A |
| Gross Profit | $-1,261,000 | $7.72M | $-16,051,000 | $-4,157,000 |
| Gross Margin | -216.7% | 98.9% | -993.3% | N/A |
| Operating Income | $-95,058,000 | $-65,861,000 | $-18,710,000 | $-5,398,000 |
| Net Income | $-88,458,000 | $-67,999,000 | $-19,185,000 | $-5,196,000 |
| Net Margin | -15199.0% | -871.6% | -1187.2% | N/A |
| EPS | $-2.23 | $-3.78 | $-6.67 | $-0.51 |
Company Overview
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish0 Neutral/Bearish
Price Targets
$24
Average Target
↑ 58.9% Upside
Now
$18
Low
$24
Average
$28
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 17th 2023 | Guggenheim | Initiation | Buy | $28 |
| January 4th 2023 | Oppenheimer | Initiation | Outperform | $27 |
| June 29th 2022 | Evercore ISI | Upgrade | Outperform | $18 |
Earnings History & Surprises
ICVXBeat Rate
30%
Last 10 quarters
Avg Surprise
-20.3%
EPS vs Estimate
Beats / Misses
3/6
1 met exactly
Latest EPS
$-0.44
Q4 2023
EPS Surprise History
Q1 22
-9.5%
$-0.46vs$-0.42
Q2 22
-22.4%
$-0.60vs$-0.49
Q3 22
-3.6%
$-0.57vs$-0.55
Q4 22
+3.5%
$-0.55vs$-0.57
Q1 23
-1.7%
$-0.59vs$-0.58
Q2 23
0.0%
$-0.60vs$-0.60
Q3 23
+1.7%
$-0.59vs$-0.60
Q4 23
+22.8%
$-0.44vs$-0.57
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2024 | Apr 4, 2024 | $-0.54 | — | — | — |
Q4 2023 | Nov 14, 2023 | $-0.57 | $-0.44 | +22.8% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.60 | $-0.59 | +1.7% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $-0.60 | $-0.60 | 0.0% | = MET |
Q1 2023 | Mar 30, 2023 | $-0.58 | $-0.59 | -1.7% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.57 | $-0.55 | +3.5% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-0.55 | $-0.57 | -3.6% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-0.49 | $-0.60 | -22.4% | ✗ MISS |
Q1 2022 | Mar 30, 2022 | $-0.42 | $-0.46 | -9.5% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-0.49 | $-1.30 | -165.3% | ✗ MISS |
Q3 2021 | Sep 13, 2021 | $-2.23 | $-2.86 | -28.3% | ✗ MISS |
Q1 2021 | Mar 31, 2021 | — | $-1.96 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-1.60 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-1.87 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-1.74 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-0.23 | — | — |
Latest News
Loading news...
Frequently Asked Questions about ICVX
What is ICVX's current stock price?
Icosavax, Inc. (ICVX) is currently trading at $15.31 per share. The stock has moved -0.91% today.
What is the analyst price target for ICVX?
The average analyst price target for ICVX is $27.00, based on 1 analyst.
What sector is Icosavax, Inc. in?
Icosavax, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ICVX's market cap?
Icosavax, Inc. has a market capitalization of $0.77 billion, making it a small-cap company.
Does ICVX pay dividends?
No, Icosavax, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALBO
Albireo Pharma, Inc.
$44.15
Mkt Cap: $0.9B
ASLN
ASLAN Pharmaceuticals Limited
$0.60
Mkt Cap: $0.2B
CDMO
Avid Bioservices, Inc.
$12.49
Mkt Cap: $0.8B
CMRX
Chimerix, Inc.
$8.54
Mkt Cap: $0.8B
EXAI
Exscientia plc
$4.84
Mkt Cap: $0.6B
HARP
Harpoon Therapeutics, Inc.
$23.01
Mkt Cap: $0.9B
ICPT
Intercept Pharmaceuticals, Inc.
$19.00
Mkt Cap: $0.8B
IKNA
Ikena Oncology, Inc.
$17.16
Mkt Cap: $0.7B
PSTX
Poseida Therapeutics, Inc.
$9.50
Mkt Cap: $0.9B
VERV
Verve Therapeutics, Inc.
$11.13
Mkt Cap: $1.0B
Explore stocks similar to ICVX for comparison